GlassScriptPhysician profile
Edsel Jeronimo Comenencia
NPI 1942201561
$4,902.14
in general payments reported to CMS, 2019-2025
27 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $733 · 2021: $795 · 2022: $613 · 2023: $876 · 2024: $668 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820 · Education: $5.55 · Travel and Lodging: $3.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.73 |
| Education | $5.55 |
| Travel and Lodging | $3.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $761.73 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $661.21 | 2019-2025 | Jardiance, Mounjaro |
| Novo Nordisk INC | $553.11 | 2020-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $488.80 | 2019-2022 | |
| Amarin Pharma, INC. | $421.65 | 2019-2021 | |
| Abbott Laboratories | $330.56 | 2021-2024 | Freestyle Libre, Cardiomems |
| Merck Sharp & Dohme LLC | $294.18 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Abbvie INC. | $266.36 | 2019-2024 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.99 | 2019-2023 | Jardiance |
| Pfizer INC. | $238.45 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $111.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.22 | 2021-2022 | |
| Abiomed | $69.74 | 2025 | |
| Astellas Pharma US INC | $47.55 | 2023-2024 | Veozah |
| Phadia US INC. | $45.83 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43.50 | 2024 | Trelegy Ellipta |
| Paratek Pharmaceuticals, INC. | $37.59 | 2024-2025 | Nuzyra, Xhance |
| Amgen INC. | $30.72 | 2019-2025 | Otezla, Repatha |
| Exact Sciences Corporation | $19.67 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $19.57 | 2020 | |
| Alk-Abello, INC | $19.52 | 2025 | Grastek, Ragwitek, Odactra |
| Esperion Therapeutics, INC. | $17.11 | 2021 | |
| Allergan, INC. | $16.16 | 2019 | |
| Genentech USA, INC. | $15.09 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.98 | 2021 | |
| Vistapharm, INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edsel Comenencia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.